PMF patients with concurrent JAK2 and IDH1-IDH2 mutations have shorter leukemia-free survival [74], thus suggesting that co-mutations in JAK2 and IDH1-IDH2 could cooperate to promote MPN progression and transformation. Here, IDH1 is linked to myeloproliferative neoplasm.